Navigation Links
Kiadis Pharma Reports Successful End of Phase II Meeting With FDA for Reviroc
Date:12/19/2007

FDA Offers Special Protocol Assessment for Reviroc

AMSTERDAM, December 19 /PRNewswire/ -- Kiadis Pharma announced today that it has successfully completed an End of Phase II meeting for Reviroc with the U.S. Food and Drug Administration (FDA). Reviroc is under development for elimination of cancer cells from an autologous graft in bone marrow transplantations for end-stage blood cancer patients. The FDA agreed that the data from the completed phase II clinical Reviroc trial is sufficient to support the start of a phase III study. The FDA offered Kiadis Pharma its Special Protocol Assessment (SPA) procedure allowing Kiadis Pharma to work directly with the FDA to optimize the clinical design of the trial.

The FDA meeting followed the successful completion of a multi centre phase II study for Reviroc showing an improved overall survival after autologous bone marrow transplantation in Non-Hodgkin's lymphoma patients. The phase III clinical trial design for Reviroc will focus on patients with Large B cell lymphoma. Kiadis Pharma anticipates filing of the IND, SPA request and Orphan Drug Designation application with the FDA within the next few weeks.

"We are very pleased with the outcome of the End of Phase II meeting with the FDA and with the possibility to access the FDA's Special Protocol Assessment program. Together with the strong support by our principal investigators we are well prepared to design a clear path towards marketing authorization for Reviroc," said Manja Bouman, CEO Kiadis Pharma.

About Reviroc

Reviroc is being developed as a treatment that eliminates blood cancer cells from autologous transplants for patients with end stage blood cancer. An autologous transplant uses the patient's own bone marrow to serve as a graft. Bone-marrow transplants are broadly recognized as a treatment option for patients suffering from blood cancers, such as leukemia and lymphoma. One of the limitations of autologous bone mar
'/>"/>

SOURCE Kiadis Pharma
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
5. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... ... September 03, 2015 , ... ... non-invasive hydration monitoring wearable early 2016. , The device, called the Halo ... proprietary optical and electrical sensing technology. These sensors track trending interstitial fluid levels ...
(Date:9/2/2015)... , Sept. 2, 2015 Research ... the addition of Jain PharmaBiotech,s new report ... to their offering. An ... and biotechnology industries is anticipated. Nanotechnology will ... development - from formulations for optimal delivery ...
(Date:9/2/2015)... DUBLIN , Sep. 02, 2015 ... ) has announced the addition of Jain PharmaBiotech,s ... Markets and Companies" to their offering. ... markets based on technologies and applications. The report ... basis for estimation of markets. Technologies include array ...
(Date:9/2/2015)... , Sep. 02, 2015 ... addition of Jain PharmaBiotech,s new report "Gene Therapy ... The markets for gene therapy are difficult ... therapy product and it is marketed in ... estimated for the years 2014-2024. The estimates are based ...
Breaking Biology Technology:Technology Startup Halo Wearables to Unveil Non-Invasive Hydration Monitoring Device Early 2016 2Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 2Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 3Global Biochips and Microarrays Technologies, Markets and Companies Report 2015 with Market Size in 2014 and Projected Value for the Years 2019 and 2024 2Global Gene Therapy Market Study 2015-2024 - Technologies, Markets and Companies Analysis 2
... Hospital UCLA today announced the launch of the ... future of personalized medicine for children, including the ... of the world,s first dedicated solely to nanomedicine ... develop a nanopediatrics program? Because children are not ...
... presented at American Society of Anesthesiologists Annual Meeting ... (SpHb) and Oxygen Content (SpOC) monitor with live ... ... Masimo, the inventor,of Pulse CO-Oximetry(TM) and Measure-Through-Motion-and-Low-Perfusion pulse,oximetry, announced ...
... /Xinhua-PRNewswire-FirstCall/ --,Shengtai Pharmaceutical, Inc. (OTC Bulletin Board: ... and distributor of high-quality,pharmaceutical grade glucose products ... factory improvements providing technological and environmental,best practices ... Company,s improvement of the water treatment program ...
Cached Biology Technology:Mattel Children's Hospital UCLA launches program in nanopediatrics 2Five New Clinical Studies Show Value of Masimo PVI & PI 2Five New Clinical Studies Show Value of Masimo PVI & PI 3Five New Clinical Studies Show Value of Masimo PVI & PI 4Five New Clinical Studies Show Value of Masimo PVI & PI 5Shengtai Pharmaceutical Completes Factory Improvements Resulting in Operational and Environmental Benefits 2Shengtai Pharmaceutical Completes Factory Improvements Resulting in Operational and Environmental Benefits 3
(Date:9/2/2015)... California , September 2, 2015 ... the security purpose implied in a system which ... geometry, voice, signature, iris, vein, DNA and finger ... has forced to develop such system which provides ... username, password, PIN, Patterns and tokens are vulnerable ...
(Date:8/28/2015)... India , August 28, 2015 ... Assessment and Training Market by Assessment Type (Pen & ... Learning, Brain Training, Corporate Learning, Academic Research), Vertical and ... Cognitive Assessment and Training Market to grow from USD ... 2020, at a Compound Annual Growth Rate (CAGR) of ...
(Date:8/24/2015)... , Aug. 24, 2015  Based on its recent ... DERMALOG with the 2015 African Biometrics Company of the Year ... achieved substantial commercial success in Africa . ... , where it has implemented one of the largest biometric ... as well as the Central Bank of Nigeria ...
Breaking Biology News(10 mins):Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 2Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 3Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 4Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 2Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 3Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 4Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 2Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 3Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 4Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 5Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 6
... something extremely bittereven if you don,t swallow it at allis ... set your stomach churning, according to a new study reported ... Press publication. "This work shows that our body and ... even if those foods contain toxins or anti-nutrients," said Paul ...
... sends the human immune system into overdrive it can ... and thrive inside our digestive system. New research suggests ... significant role in triggering the innate immune system to stay ... in the face of an infection. But exactly how ...
... Periodontal ligament stem cells (PDLSCs) have been found ... clinically tested dental tissue-derived stem cells, reports a study ... (20:2), freely available on-line at http://www.ingentaconnect.com/content/cog/ct/ . ... PDLSCs into beagle dogs modeled with advanced periodontal (gum) ...
Cached Biology News:Bitterness induces nausea, swallowing not required 2Stress wrecks intestinal bacteria, could keep immune system on idle 2Periodontal stem cell transplantation shows promise 2
Desmosomal Protein Immunogen: Full length, native protein purified from human epidermal keratins. Storage: -20 C, Avoid Freeze/Thaw Cycles...
PPIF Antibody...
Anti-ADAM-12 (Meltrin Alpha); amino terminal region; rabbit host...
Dual Color Mouse anti-Human Anti-Kappa FITC/CD19 PE Class: Antibody Product Group: Immunogluobulin...
Biology Products: